Ranitidine

What is Ranitidine?

Ranitidine was a medicine that belonged to a drug class called histamine H2-receptor antagonists, often referred to as H2 blockers. H2 blockers work by blocking histamine receptors in the stomach lining, which reduces the amount of acid the stomach produces.

Before its withdrawal, ranitidine was commonly used for conditions involving excess stomach acid, including:

• Heartburn and gastroesophageal reflux disease (GERD)
• Treatment and prevention of stomach and duodenal ulcers
• Erosive esophagitis caused by acid reflux
• Zollinger-Ellison syndrome and other conditions involving excess acid production

Formulations that were previously available included oral tablets, effervescent tablets, oral syrup, and an injectable form.

What Was the Recommended Dosage of Ranitidine?

Historically, ranitidine dosage was individualized based on the specific condition being treated, the patient’s age, and kidney function, since the drug was cleared from the body primarily through the kidneys.

This information is provided for context only. Because ranitidine is no longer approved or available, no current dosing guidance applies, and patients should not attempt to source or use ranitidine based on historical dosing information.

How Ranitidine Worked

Ranitidine worked by blocking histamine H2-receptors on acid-producing cells in the stomach lining. Histamine normally signals these cells to release acid; by blocking this signal, ranitidine reduced the amount of acid produced, which helped relieve symptoms of excess stomach acid and supported healing of irritated tissue in the esophagus or stomach.

This mechanism is the same general class of action still used by other currently available H2 blockers, such as famotidine.

Is a Prescription Required to Buy Ranitidine Online?

No — ranitidine should not be purchased from any source, online or otherwise. It is not an approved product in the U.S. or in many other countries. Any ranitidine offered for sale online should be treated with serious caution, as it is likely to be an unregulated, expired, or counterfeit product that has not been evaluated for safety. Because ranitidine’s NDMA contamination risk increases with age and storage conditions, any existing or informally sourced ranitidine may carry an even higher risk than the original products that were withdrawn.

Patients seeking to manage heartburn, GERD, or ulcer symptoms should consult a licensed medical professional, such as a gastroenterologist or general physician, about currently approved alternatives.

Side Effects That Were Associated With Ranitidine

Common Side Effects (Historical)

When ranitidine was in use, its most commonly reported side effects included:

• Headache
• Dizziness
• Constipation or diarrhea

Serious Concerns

The primary serious concern that led to ranitidine’s withdrawal was long-term exposure to NDMA, a probable human carcinogen, which could increase in ranitidine products over time and with storage at higher-than-room temperatures. This was a product quality and contamination issue rather than a typical side effect of the active ingredient itself.

Other serious effects that had been reported with H2 blockers as a class, in rare cases, included:

• Signs of a severe allergic reaction, such as swelling of the face or throat, or difficulty breathing
• Liver problems, such as unusual fatigue or yellowing of the skin or eyes
• Effects on heart rhythm, including irregular heartbeat, in rare cases

Patients who were previously taking ranitidine and now experience any unusual or concerning symptoms should contact their doctor.

Drug Interactions (Historical Reference)

Ranitidine, like other H2 blockers, was known to interact with medications that depend on stomach acid for absorption, as well as certain other drugs. This information is provided for historical reference only and should not guide any current treatment decisions.

Safety & Important Considerations

• NDMA contamination: The core safety concern with ranitidine was the presence of NDMA, a probable human carcinogen, at levels that could increase over the product’s shelf life and with storage above room temperature. This is why the FDA requested a full market withdrawal rather than issuing a standard warning.
• No current dosing or monitoring guidance applies, since the product is not approved for use.
• Approved alternatives exist. According to FDA testing at the time of the withdrawal, NDMA was not found in several alternative acid-reducing medicines, including famotidine, cimetidine, esomeprazole, lansoprazole, and omeprazole.
• Patients previously on ranitidine should not stop or switch treatment without medical guidance, since untreated acid-related conditions can worsen. A doctor can recommend an appropriate, currently approved alternative.

Who This Medication Was For

Ranitidine was previously prescribed for individuals with GERD, stomach or duodenal ulcers, erosive esophagitis, and Zollinger-Ellison syndrome. It is no longer an appropriate treatment option for any patient population, given its withdrawal from the market.

Who Should Not Use Ranitidine

No patient should use ranitidine today. It is not approved for use in the U.S. or in many other countries due to the NDMA contamination concern described above. This applies regardless of a patient’s medical history, age, or condition.

What to Do If You Have Leftover Ranitidine

If a patient or caregiver has old ranitidine tablets or liquid at home:

• Do not take it.
• Dispose of it properly, following local guidance for medication disposal (for example, a pharmacy take-back program), rather than simply discarding it in household trash or flushing it, unless otherwise instructed by local disposal guidelines.
• Do not purchase more ranitidine to replace it.
• Speak with a doctor about switching to a currently approved alternative for ongoing symptom management.

Related medications to Ranitidine

Currently available medications in the same or related therapeutic classes that may be considered for acid-related conditions include:

• Other H2 blockers (such as famotidine or cimetidine), which were not found to contain NDMA in FDA testing
• Proton pump inhibitors (such as omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, or dexlansoprazole)
• Potassium-competitive acid blockers (such as vonoprazan), a newer class of acid-suppressing medicine
• Antacids, for short-term relief of mild, occasional symptoms
• Lifestyle and dietary modifications, which are often recommended alongside or instead of medication for mild cases

Any switch to a new treatment should be made in consultation with a licensed medical provider, who can recommend the most appropriate currently approved option based on the individual’s health history.

Storage Instructions

Ranitidine products were previously advised to be stored at room temperature and protected from heat and moisture, since heat exposure was later found to accelerate NDMA formation. This information is provided for historical context only, as the product is no longer available for use.

Disclaimer:

This page is intended for educational purposes only and does not constitute medical advice. Ranitidine is not currently approved for sale or use in the United States and has been withdrawn from the market due to safety concerns. Patients and caregivers must consult a licensed physician or gastroenterologist regarding any questions about past ranitidine use or about starting a currently approved alternative treatment. All treatment decisions should be based on a full clinical evaluation by a qualified healthcare provider who is familiar with the patient’s individual medical history.